• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

TiGenix - Articles and news items

crohns-disease

TiGenix’s Crohn’s disease drug granted Swiss orphan drug designation

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn’s disease that have…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

Takeda & TiGenix announce Perianal Fistulas trial treatment results for Crohn’s disease

Industry news / 2 August 2016 / Takeda Pharmaceutical Company Limited / TiGenix NV

Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease…

cx601

Takeda enters into licensing agreement for ex-US rights to Cx601

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

TiGenix’s Phase III trial design for Cx601 endorsed by President-Elect of ECCO

Industry news / 23 February 2015 / TiGenix NV

TiGenix NV has announced that Dr Julian Panés endorsed the design of the Company’s Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn’s disease during his presentation last week at the 10th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease

Supplier news / 13 February 2015 / TiGenix

Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix’s eASC product, Cx601.  Under the agreement, Lonza will manufacture material for […]

TiGenix

TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule

Industry news / 12 November 2014 / TiGenix NV

TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn’s patients…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +